



# Proteomics of nucleocytoplasmic partitioning

Thao Nguyen, Nishant Pappireddi and Martin Wühr

The partitioning of the proteome between nucleus and cytoplasm affects nearly every aspect of eukaryotic biology. Despite this central role, we still have a poor understanding of which proteins localize in the nucleus and how this varies in different cell types and conditions. Recent advances in quantitative proteomics and high-throughput imaging are starting to close this knowledge gap. Studies on protein interaction are beginning to reveal the spectrum of cargos of nuclear import and export receptors. We anticipate that it will soon be possible to predict each protein's nucleocytoplasmic localization based on its importin/exportin interactions and its estimated diffusion rate through the nuclear pore. This insight is likely to provide us with a fundamental understanding of how cells use nucleocytoplasmic partitioning to encode and relay information.

## Address

Department of Molecular Biology & the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA

Corresponding author: Wühr, Martin ([wuhr@princeton.edu](mailto:wuhr@princeton.edu))

**Current Opinion in Chemical Biology** 2019, **48**:55–63

This review comes from a themed issue on **Omics**

Edited by **Ileana M Cristea** and **Kathryn S Lilley**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 23rd November 2018

<https://doi.org/10.1016/j.cbpa.2018.10.027>

1367-5931/© 2018 Elsevier Ltd. All rights reserved.

## Introduction

The subdivision of the cell into compartments with distinct contents and functions is one of the key hallmarks of eukaryotic biology [1]. A double-layered membrane, the nuclear envelope (NE), separates the nucleus from the rest of the cell. The NE is perforated by thousands of nuclear pore complexes (NPCs), which control the exchange of nuclear and cytoplasmic content by allowing the selective passage of some molecules, while being nearly impermeable to others. This spatial separation of biochemical pathways allows eukaryotes to have additional layers of regulation not available to prokaryotes [2]. Nucleocytoplasmic (NC) partitioning can encode cellular information, similar to protein expression levels or protein phosphorylation. For instance, the activation of the canonical Wnt signaling pathway leads to accumulation of  $\beta$ -catenin in the nucleus, resulting in downstream gene


activation. Kinase activity can also be regulated via subcellular localization: cyclin B needs to relocalize into the nucleus to induce NE breakdown, which is required for the transition from G2 to mitosis [3]. Considering the importance of subcellular localization in encoding important cellular information, it is not surprising that misregulation of nuclear transport has been associated with multiple diseases, including developmental defects and cancer [4–6]. Targeting misregulation of NC partitioning has emerged as a promising therapeutic approach, particularly for cancer treatment [7–11].

Many previous studies have reported this subcellular localization of individual proteins. Recent technological advances in methods such as mass spectrometry (MS) now allow us to look at the entire proteome at once. This global approach allows the observation of protein localization in a wider context. This might reveal emerging principles, which are impossible to observe otherwise. For example, we might discover a set of proteins that localize in an unexpected manner, pointing towards a so far unknown nuclear localization mechanisms. In this review, we will discuss our current knowledge about NC partitioning and highlight the responsible nuclear transport mechanisms. We will focus on the proteome-wide scale and discuss the emerging technologies that might be able to close the considerable gaps that remain in our knowledge.

## Which proteins constitute the nuclear proteome?

Various resources are currently available that annotate the composition of the nuclear proteome. An emerging source for subcellular localization data comes from quantitative proteomics studies. MS provides a tool to quantify relative protein abundances for thousands of proteins in a single experiment. Quantifying NC distribution with MS relies on the ability to reliably fractionate cells into the nucleus and cytoplasm. Cleanly separating nuclei from the rest of the cell is surprisingly difficult. Once a nucleus is removed from a somatic cell, the time it takes some proteins to diffuse through the nuclear pore is believed to be short compared to the time it takes for standard nuclear isolation protocols for example, via centrifugation through a sucrose cushion [12,13]. Additionally, ruptures in the nuclear envelope resulting from cell lysis might lead to additional loss of soluble nuclear proteins. The unusually large frog oocyte (~1 mm diameter) allows for the rapid and faithful isolation of the nucleus via physical methods and is therefore uniquely suited for proteomics experiments (Figure 1a). Taking advantage of this system, we previously quantified nucleocytoplasmic partitioning for

Figure 1



What we know about the distribution of the proteome between nucleus and cytoplasm.

**(a)** An MS-based method for proteome-wide quantification of protein partitioning between the nucleus (blue) and cytoplasm (rest of cell) in an amphibian oocyte. The exceptionally large nuclei can be easily and rapidly isolated without loss of material. With quantitative proteomics, the relative concentration of proteins in the nucleus and cytoplasm can be quantified. **(b)** Comparison of overlap of nuclear localization prediction of human proteins from three resources. UniProt is curated from the literature, Cell Atlas predictions are based on immunofluorescence in tissue culture cells, and Wühr *et al.* quantified nucleocytoplasmic partitioning with quantitative proteomics in the frog oocyte, which were then matched to human genes [14\*\*,23\*,24\*\*]. A consensus on nuclear localization is emerging for a significant number of proteins but, for many others, the data is contradictory or missing. **(c)** Reconstruction of subcellular localization based on crude fractionation of cell lysate for example, HyperLOPIT [35\*\*]. Proteins from the same organelles are typically not fully separated but often show characteristic fractionation patterns. The elution profile is read out with quantitative proteomics. Based on this profile, proteins are assigned to organelles. **(d)** Comparison of nuclear localization from physical isolation in the frog oocyte [14\*\*] or in mouse pluripotent stem cell with HyperLOPIT [35\*\*]. Shown is the histogram based on subcellular localization quantification in the frog oocytes for proteins that were measured in both studies (black). The proteins predicted to be nuclear by HyperLOPIT (blue shaded area) show remarkable agreement with the data obtained in frogs. However, for about a third of the frog nuclear proteins quantified in both studies, HyperLOPIT does not make predictions about subcellular localization (orange shaded area on top of the blue).

~9k proteins in the frog oocyte with two state-of-the-art methods of quantitative proteomics [14\*\*,15\*,16\*]. The quantified frog proteins were then matched to human gene symbols for easy comparison to other databases.

For many years, studies have determined the localization of individual proteins of interest via immunofluorescence, GFP-fusion proteins, or Western Blotting [17–20]. Various sources like UniProt, Gene Ontology, or LocDB have curated these studies into subcellular localization databases [21,22,23\*]. UniProt contains subcellular information for ~17k human proteins (~5k nuclear) (Figure 1b). Equally large and widely-used as the UniProt database, Gene Ontology has the information of ~5k nuclear proteins among ~20k human entries. Another subcellular localization database, LocDB, provides subcellular localization annotations for ~13k human proteins in which ~5k of them are nuclear. Recently, the Human Cell Atlas

Consortium has attempted to generalize the immunofluorescence approach by raising antibodies against every human protein [24\*\*]. So far, the consortium has been able to annotate the subcellular localization of ~12k human proteins based on immunofluorescence in human tissue culture cells. Of these, ~7k were identified as nuclear (Figure 1b). Unlike the categorical information made available by UniProt or Cell Atlas, quantitative proteomics determines the concentration ratio between the nucleus and cytoplasm. Because of the limited sensitivity of proteomics, however, the total number of proteins for which information is available is comparatively small. When comparing the predictions from these three resources, it is apparent that a consensus of proteins constituting the nuclear proteome starts to emerge (Figure 1b). Surprisingly, however, information about the subcellular localization of many proteins is either unavailable, limited to a single source, or contradictory

between different sources. Some of the discrepancies might be simply due to measurement errors, caused, for instance, by non-specific antibody staining. Alternatively, it is possible, or even likely, that for many proteins, subcellular localization depends on cell type or environmental conditions. Apparent disagreement might be due to interesting biological differences.

An important question for the field is how much the nuclear proteome composition differs in various cell types and conditions. MS-based proteomics is the technique which will likely be employed to answer such questions, as it is currently the only approach that allows quantification of thousands of proteins in a single experiment at a moderate cost.

While highly valuable as a model system, the frog oocyte is unusually large and rather specialized; hence, the methods for quantification of subcellular localization cannot be fully transferred to small cells, for which nuclei cannot be isolated manually. An elegant approach to overcome the difficulty of isolating individual organelles from small cells is the use of crude fractionation to assign proteins to their compartments (Figure 1c). This method is compatible with a wide range of cell types and potentially tissue lysates. These approaches typically use density gradient centrifugation to fractionate cell lysates. Protein complexes and organelles are separated based on their size and density. The acquired fractions are differentially labelled with isobaric tags for an MS experiment [25]. Isobaric tags like TMT barcode different conditions for example, fractions [26]. This allows the co-analysis of multiple samples in a single experiment, which drastically improves measurement precision. Recent progress in multiplexed proteomics technology allows the accurate quantification of ~9k proteins among ~10 conditions with typical coefficients of variation of ~5% [15<sup>•</sup>,27–29]. The centrifugation profile for each protein is read out with quantitative MS and proteins are assigned to compartments based on the similarity of their profiles to organelle-reference proteins [30,31]. This approach has been used to map subcellular localization in multiple eukaryotic cell lines ranging from plants [32], invertebrates [33], vertebrates [34], to mammalian cells such as mouse pluripotent stem cells [35<sup>••</sup>], mouse and rat liver cells [36,37], and HeLa cells [38]. Comparison of the categorical nuclear data of one such study (HyperLOPIT) [35<sup>••</sup>] with the quantitative data from the frog oocyte shows a remarkable agreement for proteins that are predicted to be nuclear (Figure 1d). However, no predictions can be made for ~1/3 of frog nuclear proteins detected by HyperLOPIT, likely due to unassignable gradient profiles. These unassignable profiles likely result from proteins exhibiting different elution profiles than any of the reference protein sets. This is likely due to (partial) disassembly of organelles during the lysis/fractionation, differential behavior of sub organelle structures, loss of


protein–protein interactions due to dilution, proteomics measurement errors, and so forth. Perhaps it will be possible to further improve HyperLOPIT-like approaches by using gentler lysis conditions or by adding complementary fractionation techniques. Another important limitation is that approaches like HyperLOPIT are currently non-quantitative. Nevertheless, it has been shown that, at least in principle, relative abundance between multiple compartments can be inferred [37].

### How do nuclear transport pathways give rise to the observed nucleocytoplasmic partitioning of the proteome?

As proteins are exclusively synthesized in the cytoplasm [39], nuclear content is strictly dependent on nuclear pore passage. Based on energy consumption, one can differentiate transport through the NPC into passive diffusion and active transport. Passive diffusion involves the bidirectional and energy-free movement of molecules through NPCs. If diffusion rates are relatively fast compared to protein lifetimes, passive diffusion is expected to lead to equimolar concentrations in the nucleus and cytoplasm. However, if local binding to a structure (e.g. DNA) exclusive to the nucleus or cytoplasm acts as a sink, passive diffusion can lead to asymmetric protein concentrations (Figure 2a). Einick and Bustin demonstrated that a histone antibody fragment heavily enriches in the nucleus even though it was inert to active nuclear transport [40]. It is unclear to what extent this mechanism is responsible for differential nucleocytoplasmic concentrations of the cell's proteome.

In contrast to passive diffusion, active transport is strictly regulated, directional, and ultimately energy-dependent. This system requires continuous consumption of energy to maintain a RanGTP gradient between the nucleus and cytoplasm [41]. The gradient is controlled by the restricted localization of RanGAP (which hydrolyzes RanGTP into RanGDP) and RanGEF (which converts RanGDP into RanGTP), which leads to a steep concentration gradient of RanGTP across the NE. RanGEF is bound to the DNA to restrict its localization and results in the high concentration of RanGTP in the nucleus [42,43]. Importins and exportins acting as nuclear transport receptors utilize this gradient to selectively transport cargo into or out of the nucleus (Figure 2b)[44]. The characteristic stretch of amino acids on cargos that allows recognition by importin is called the nuclear localization signal (NLS) and can often be predicted bioinformatically [45<sup>•</sup>]. When we overlay current knowledge of nuclear transport pathways with the NC partitioning distribution in the frog oocyte, we can observe some of the expected correlation but also surprising discrepancies (Figure 3a)[14<sup>••</sup>]: ~17% of the oocyte proteins show roughly the same concentration in nucleus and cytoplasm. The majority of these proteins are in complexes less than ~100 kDa in molecular weight, suggesting that they passively diffuse through

Figure 2



Schematic of molecular mechanisms responsible for the establishment and maintenance of nucleocytoplasmic partitioning.


**(a)** Small proteins are believed to be able to diffuse rapidly through the nuclear pore. Typically, this would lead to equal concentration in the nucleus and cytoplasm (green). However, with a local sink (e.g. binding to DNA) or localized assembly into large complexes, passive diffusion leads to enrichment of proteins in one compartment (orange). **(b)** Principle of active directional transport over the nuclear pore. The restricted localization of RanGAP in the cytoplasm and RanGEF in the nucleus, in particular on the DNA, maintains a steep concentration gradient of RanGTP across the NE. Importins bind cargo in the cytoplasm. The importin-substrate complex can diffuse through the nuclear pore comparatively rapidly. In the nucleus, the exchange of RanGDP to RanGTP leads to a conformational change in the importin, resulting in the release of its cargo protein. **(c)** Similarly, but in the opposite direction, exportin together with RanGTP binds to its cargo substrate in the nucleus and rapidly diffuses outward through the nuclear pore complex. In the cytoplasm, RanGAP hydrolyzes RanGTP and leads to the exportin's release of its cargo.

the NPC to equidistribute. However, some notable large complexes, like the proteasome, are also equidistributed. Perhaps these complexes diffuse as monomers, or they might be able to permeate through the NPC despite their size. Alternatively, they may be actively transported in both directions. Less than 60% of oocyte nuclear proteins are bioinformatically predicted to carry an NLS [45<sup>•</sup>] (Figure 3a). It is unclear if the remaining proteins in the nucleus have an undetectable NLS (e.g. cryptic 3D import signals), if there exists a localized binding sink, or if these proteins piggyback into the nucleus with others. Furthermore, nearly as many cytoplasmic proteins contain bioinformatically predicted NLSs as those in the nucleus (Figure 3a). Among them are ribosomal proteins, which are known to be imported into the nucleus as monomers. Upon assembly into ribosomal subunits, the NLSs are hidden, and exportins transport these subunits to the cytoplasm [46]. It will be exciting to learn why so many other proteins in the cytoplasm appear to carry an apparent NLS. The open questions outlined in Figure 3a can be addressed and possibly resolved by studying the

contribution of nuclear transport pathways to the nucleocytoplasmic localization of the cell's proteome.

Rules for passive diffusion through NPCs have been extrapolated from measurements of a handful of proteins or reporter molecules [47<sup>•</sup>,48<sup>••</sup>,49<sup>•</sup>]. Based on measurements in HeLa cells, the Görlich group proposed that the passive diffusion can be modeled with a mixture of characteristic pore sizes (Figure 3b) [48<sup>••</sup>]. The Rout group observed that, in yeast, GFP multimers of increasing size passively diffuse with times that relate to a power-law [49<sup>•</sup>]. However, there is no molecular explanation behind this observation and many graphs follow this relationship (Figure 3b). In Figure 3b, we plotted the expected diffusion half-time for spherical proteins as a function of their molecular weight. Interestingly, the models either do not agree with previous halftime measurements, or need to be fitted with a free parameter [47<sup>•</sup>,50]. Even if this free parameter is fitted, it is not obvious why proteins smaller than 100 kDa are nearly always equidistributed (Figure 3a) whereas nearly all


Figure 3



How does the interplay of nuclear trafficking pathways lead to observed nucleocytoplasmic partitioning?

**(a)** Observed nucleocytoplasmic partitioning in the frog oocyte for all detected proteins and proteins that contain a bioinformatically predicted NLS or for proteins in complexes smaller than 100 kDa [14<sup>\*\*</sup>,45<sup>\*</sup>]. Quantification of the concentration in the nucleus over the summed concentration in the nucleus and cytoplasm using the *Xenopus* oocyte model reveals a trimodal distribution for all ~9k proteins observed (black line). The majority of proteins localize nearly exclusively in either the cytoplasm or the nucleus. The majority of the equidistributed proteins were shown to be in complexes smaller than ~100 kDa and are likely to rapidly diffuse through the nuclear pore (blue line). Interestingly, proteins that are bioinformatically predicted to carry an NLS [45<sup>\*</sup>] are nearly as likely to be present in the nucleus or cytoplasm but very unlikely to be equidistributed (red line). **(b)** Comparison of diffusion half-time of a few measured proteins and dextrans to the proposed models for size-dependent diffusion times from separate studies [47<sup>\*</sup>,48<sup>\*\*</sup>,49<sup>\*</sup>,50]. The black dots depict the measured diffusion half-time based on radiography of proteins or dextrans, converted into protein-molecular weight based on matching of Stokes radii [47<sup>\*</sup>,50]. The curves are the predictions of a protein's diffusion half-time through the NPCs: in red are the empirical power law relationship between diffusion time constant and protein size with different coefficients presented in different dashed red curves [49<sup>\*</sup>]. The blue line depicts how the interplay between the protein's size and the pore complex affects the protein's diffusion half-time in the model where the nuclear pore is modelled with three distinct pore sizes with their associated frequencies [48<sup>\*\*</sup>]. The models only poorly predict experimental diffusion times in this system. Furthermore, based on these models it is not apparent why proteins in complexes smaller than ~100 kDa (blue vertical line) are equidistributed while nearly all proteins exclusive to one compartment are in larger assemblies. **(c,d)** Principle of identifying cargos for importin/exportin on the example of exportin 1 (XPO1) [57<sup>\*\*</sup>]. **(c)** Cell lysate is exposed to XPO1 in the binding form (with RanGTP) or to XPO1 which cannot bind substrates. XPO1 is linked to an affinity tag, which allows easy isolation for example, via magnetic beads. **(d)** Shown is the coomassie gel of eluates of Exportin 1 pull-downs +/- RanGTP. Bands with equal intensities in both lanes are likely due to non-specific binding. True substrates are expected to show significantly higher abundance in the right lane. With quantitative proteomics, the identity and relative enrichment of each of these bands and many more can be resolved. Reprinted with friendly permission from eLife [57<sup>\*\*</sup>].

Figure 4



Towards an understanding of how the cell partitions its proteome between nucleus and cytoplasm on a global scale with molecular resolution. **(a)** We can predict many physicochemical properties of proteins from primary sequences and protein structures [61]. These properties can be correlated to their nuclear transport behaviors for example, *TOP* - the size/shape of proteins (complexes) and their surface properties can be converted to a model that predicts the passive diffusion time through the nuclear pore. *BOTTOM* - additionally, the expression levels of all importins/exportins along with the identity and affinity of their substrates can be determined bioinformatically or experimentally. **(b)** Together, this should allow us to predict transport for each protein through NPCs and thereby predict their nucleocytoplasmic partitioning. A satisfying model would generate predictions that are very similar to actual measurements. Differences between observed and predicted partitioning could point towards a substantial lack of understanding and provide direction toward new, overlooked mechanisms.

proteins that are exclusive to the nucleus or cytoplasm are larger than  $\sim 100$  kDa [14\*\*]. One possibility is that nuclear pores in different model systems show different permeabilities. An alternative explanation is that deducing diffusion data for all proteins from just a few model substrates might not be appropriate. Recently, the Görlich lab has shown that a protein's diffusion through NPCs can be altered drastically by modifying its surface properties [51\*\*]. Perhaps the current models for passive diffusion were built on proteins with unusual characteristics. An important task will be to resolve the apparent discrepancies in predicted passive diffusion rate as a function of protein size and potentially incorporate proteins' surface properties.

Regarding active transport, some studies have already tried to predict which proteins are substrates for particular transport pathways. In humans,  $\sim 20$  transport receptors are known. For importin pathways, a subset of NLSs can be predicted bioinformatically [45\*,52,53]. However, it remains a mystery why proteins with predicted NLSs show the observed subcellular distribution (Figure 3a). Nuclear export signal prediction algorithms have also been developed, but these predictions are even more

difficult to make [54–56]. It is possible to infer the substrate transport receptor relationships with differential pull-downs in which the transport receptor is kept in the state where it either binds or does not bind substrates (Figure 3c and d). Using this approach and quantifying the differential binding,  $\sim 1000$  substrates were identified for Exportin 1, and  $\sim 250$  for XPO7 [57\*\*,58]. Similar experiments with importins might be able to resolve the surprising NLS distribution shown in Figure 3a. In an alternative approach, the nuclear transport receptor-substrate relationship was inferred via proximity labelling [59]. It now seems plausible to map the entire interaction network of all NTRs with their substrates. It should also be possible to estimate relative affinities of all substrates to all NTRs by combining competition studies with quantitative proteomics read-outs. These measurements will be required to predict whether multiple NTRs act on the same substrate(s), or if substrates compete for binding to an NTR. We know of individual examples where differential expression of nuclear transport receptors changes the nuclear proteome composition with drastic consequences for cellular function. For example, the lack of exportin 6 expression in the mature frog oocyte leads to actin accumulation in the nucleus, which provides the

stability required for its unusually large size [60]. Knowledge of NTR expression levels could go a long way to predicting differential subcellular protein localization once we understand which NTRs interact with which cargo.

## Summary and outlook

The nucleocytoplasmic distribution of many proteins is highly dynamic and often encodes critical information during development, stress responses, and general cell signaling. Thanks to emerging technologies, which allow the assignment of subcellular localization on a proteome-wide scale, we should soon be able to answer questions such as how nucleocytoplasmic partitioning changes during differentiation or in response to perturbations. These measurements might be just as informative as protein expression and phosphorylation experiments. Besides being able to measure how proteins are distributed between the nucleus and cytoplasm, an exciting challenge is to be able to untangle the underlying mechanisms responsible for this distribution. We discussed approaches to predict the rate of passive diffusion and active transport on a proteome-wide scale with molecular resolution. Data with sufficiently high quality on active transport and passive diffusion through the nuclear pore should allow precise prediction of each protein's relative concentration between the nucleus and cytoplasm (Figure 4). Congruence between predictions and observations would be truly satisfying. Perhaps even more exciting would be any discrepancies that could suggest other nuclear transport mechanisms we cannot currently fathom.

## Conflict of interest statement

Nothing declared.

## Acknowledgements

We would like to thank Amanda Amodio, Thomas Güttler, and members of the Wühr Lab for helpful comments on the manuscript. N.P. was supported by NIH grant T32GM007388. This work was supported by NIH grant 1R35GM128813.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Martin WF, Garg S, Zimorski V: **Endosymbiotic theories for eukaryote origin.** *Philos Trans R Soc Lond B Biol Sci* 2015, **370**:20140330.
2. Macgillivray AJ, Paul J, Threlfall G: **Transcriptional regulation in eukaryotic cells.** *Adv Cancer Res* 1972, **15**:93-162.
3. Li J, Meyer AN, Donoghue DJ: **Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation.** *Proc Natl Acad Sci U S A* 1997, **94**:502-507.
4. Paciorkowski AR, Weisenberg J, Kelley JB, Spencer A, Tuttle E, Ghoneim D, Thio LL, Christian SL, Dobyns WB, Paschal BM: **Autosomal recessive mutations in nuclear transport factor KPNA7 are associated with infantile spasms and cerebellar malformation.** *Eur J Hum Genet* 2014, **22**:587-593.
5. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C: **Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.** *Cancer* 2008, **112**:1733-1743.
6. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD: **The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.** *Int J Cancer* 2009, **124**:1829-1840.
7. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M *et al.*: **Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.** *Blood* 2012, **120**:1765-1773.
8. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T: **CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.** *Blood* 2011, **118**:3922-3931.
9. Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM: **CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo.** *J Cancer* 2013, **4**:614-625.
10. Senapedis WT, Baloglu E, Landesman Y: **Clinical translation of nuclear export inhibitors in cancer.** *Semin Cancer Biol* 2014, **27C**:74-86.
11. Dickmanns A, Monecke T, Ficner R: **Structural basis of targeting the exportin CRM1 in cancer.** *Cells* 2015, **4**:538-568.
12. Paine PL, Austerberry CF, Desjarlais LJ, Horowitz SB: **Protein loss during nuclear isolation.** *J Cell Biol* 1983, **97**:1240-1242.
13. Nabbi A, Riabowol K: **Isolation of pure nuclei using a sucrose method.** *Cold Spring Harb Protoc* 2015, **2015**:773-776.
14. Wühr M, Güttler T, Peshkin L, McAlister GC, Sonnett M, Ishihara K, Groen AC, Presler M, Erickson BK, Mitchison TJ *et al.*: **The nuclear proteome of a vertebrate.** *Curr Biol* 2015, **25**:2663-2671.  
This work quantifies the nucleocytoplasmic partitioning of ~9k proteins in the frog oocyte using two different methods of quantitative proteomics. The unusually large cells allow easy and faithful nuclear isolation.
15. McAlister GC, Nusinow DP, Jedrychowski MP, Wühr M, Huttlin EL, Erickson BK, Rad R, Haas W, Gygi SP: **MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes.** *Anal Chem* 2014, **86**:7150-7158.  
This work introduced the MultiNotch MS3 quantitative multiplexed proteomics technique, which removes measurement artifacts inherent to standard multiplexed proteomics measurements.
16. Wühr M, Haas W, McAlister GC, Peshkin L, Rad R, Kirschner MW, Gygi SP: **Accurate multiplexed proteomics at the MS2 level using the complement reporter ion cluster.** *Anal Chem* 2012, **84**:9214-9221.  
This work introduced a quantitative proteomics multiplexed technique based on the complement reporter ion cluster. Similarly to MultiNotch MS3 it removes measurement artifacts but is compatible with simpler instrumentation.
17. Giepmans BN, Adams SR, Ellisman MH, Tsien RY: **The fluorescent toolbox for assessing protein location and function.** *Science* 2006, **312**:217-224.
18. Stadler C, Rexhepaj E, Singan VR, Murphy RF, Pepperkok R, Uhlen M, Simpson JC, Lundberg E: **Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells.** *Nat Methods* 2013, **10**:315-323.
19. Huh WK, Falvo JV, Gerke LC, Carroll AS, Howson RW, Weissman JS, O'Shea EK: **Global analysis of protein localization in budding yeast.** *Nature* 2003, **425**:686-691.
20. Yamauchi KA, Herr AE: **Subcellular western blotting of single cells.** *Microsyst Nanoeng* 2017, **3**.
21. Rastogi S, Rost B: **LocDB: experimental annotations of localization for Homo sapiens and Arabidopsis thaliana.** *Nucleic Acids Res* 2011, **39**:D230-234.

22. The Gene Ontology C: **Expansion of the gene ontology knowledgebase and resources**. *Nucleic Acids Res* 2017, **45**: D331-D338.
23. UniProt Consortium T: **UniProt: the universal protein knowledgebase**. *Nucleic Acids Res* 2018, **46**:2699.  
UniProt currently annotates subcellular localization for ~17k human proteins by curating data from various sources.
24. Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Bjork L, Breckels LM *et al.*: **A subcellular map of the human proteome**. *Science* 2017:356.  
The human cell atlas consortium maps the localization of ~12k human proteins to organelles using immunofluorescence.
25. De Duve C: **Tissue fractionation. Past and present**. *J Cell Biol* 1971, **50**:20d-55d.
26. Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C: **Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS**. *Anal Chem* 2003, **75**:1895-1904.
27. Sonnett M, Yeung E, Wuhr M: **Accurate, sensitive, and precise multiplexed proteomics using the complement reporter ion cluster**. *Anal Chem* 2018, **90**(8):5032-5039 <http://dx.doi.org/10.1021/acs.analchem.7b04713>.
28. McAlister GC, Huttlin EL, Haas W, Ting L, Jedrychowski MP, Rogers JC, Kuhn K, Pike I, Grothe RA, Blethrow JD *et al.*: **Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses**. *Anal Chem* 2012, **84**:7469-7478.
29. Bakalarski CE, Kirkpatrick DS: **A biologist's field guide to multiplexed quantitative proteomics**. *Mol Cell Proteomics: MCP* 2016, **15**:1489-1497.
30. Sadowski PG, Dunkley TP, Shadforth IP, Dupree P, Bessant C, Griffin JL, Lilley KS: **Quantitative proteomic approach to study subcellular localization of membrane proteins**. *Nat Protoc* 2006, **1**:1778-1789.
31. Mulvey CM, Breckels LM, Geladaki A, Britovsek NK, Nightingale DJH, Christoforou A, Elzek M, Deery MJ, Gatto L, Lilley KS: **Using hyperLOPIT to perform high-resolution mapping of the spatial proteome**. *Nat Protoc* 2017, **12**:1110-1135.
32. Dunkley TP, Hester S, Shadforth IP, Runions J, Weimar T, Hanton SL, Griffin JL, Bessant C, Brandizzi F, Hawes C *et al.*: **Mapping the Arabidopsis organelle proteome**. *Proc Natl Acad Sci U S A* 2006, **103**:6518-6523.
33. Tan DJ, Dvinge H, Christoforou A, Bertone P, Martinez Arias A, Lilley KS: **Mapping organelle proteins and protein complexes in Drosophila melanogaster**. *J Proteome Res* 2009, **8**:2667-2678.
34. Hall SL, Hester S, Griffin JL, Lilley KS, Jackson AP: **The organelle proteome of the DT40 lymphocyte cell line**. *Mol Cell Proteomics* 2009, **8**:1295-1305.
35. Christoforou A, Mulvey CM, Breckels LM, Geladaki A, Hurrell T, Hayward PC, Naake T, Gatto L, Viner R, Martinez Arias A *et al.*: **A draft map of the mouse pluripotent stem cell spatial proteome**. *Nat Commun* 2016, **7**:8992.  
This work uses subcellular protein localization assignment based on crude fractionation and quantification of elution profiles with multiplexed proteomics. The study assigns subcellular localization to ~3k proteins in mouse pluripotent stem cells.
36. Foster LJ, de Hoog CL, Zhang Y, Zhang Y, Xie X, Mootha VK, Mann M: **A mammalian organelle map by protein correlation profiling**. *Cell* 2006, **125**:187-199.
37. Jadot M, Boonen M, Thirion J, Wang N, Xing J, Zhao C, Tannous A, Qian M, Zheng H, Everett JK *et al.*: **Accounting for protein subcellular localization: a compartmental map of the rat liver proteome**. *Mol Cell Proteomics* 2017, **16**:194-212.
38. Itzhak DN, Tyanova S, Cox J, Borner GH: **Global, quantitative and dynamic mapping of protein subcellular localization**. *eLife* 2016, **5**.
39. Bohnsack MT, Regener K, Schwappach B, Saffrich R, Paraskeva E, Hartmann E, Gorlich D: **Exp5 exports eEF1A via tRNA from nuclei and synergizes with other transport pathways to confine translation to the cytoplasm**. *EMBO J* 2002, **21**:6205-6215.
40. Einck L, Bustin M: **Functional histone antibody fragments traverse the nuclear envelope**. *J Cell Biol* 1984, **98**:205-213.
41. Izaurralde E, Kutay U, von Kobbe C, Mattaj IW, Gorlich D: **The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus**. *EMBO J* 1997, **16**:6535-6547.
42. Li HY, Wirtz D, Zheng Y: **A mechanism of coupling RCC1 mobility to RanGTP production on the chromatin in vivo**. *J Cell Biol* 2003, **160**:635-644.
43. Nemergut ME, Mizzen CA, Stukenberg T, Allis CD, Macara IG: **Chromatin docking and exchange activity enhancement of RCC1 by histones H2A and H2B**. *Science* 2001, **292**:1540-1543.
44. Gorlich D, Kutay U: **Transport between the cell nucleus and the cytoplasm**. *Ann Rev Cell Dev Biol* 1999, **15**:607-660.
45. Nguyen Ba AN, Pogoutse A, Provart N, Moses AM: **NLStradamus: a simple hidden Markov model for nuclear localization signal prediction**. *BMC Bioinform* 2009, **10**:202.  
The authors provide an algorithm, based on hidden Markov models, which predicts NLSs based on protein sequences.
46. Melnikov S, Ben-Shem A, Yusupova G, Yusupov M: **Insights into the origin of the nuclear localization signals in conserved ribosomal proteins**. *Nat Commun* 2015, **6**:7382.
47. Paine PL, Moore LC, Horowitz SB: **Nuclear envelope permeability**. *Nature* 1975, **254**:109-114.  
In this study, different-size dextrans were injected into amphibian oocytes to measure the permeability of the nuclear envelope. The authors conclude that the envelope is a sieve with pore size of 4.5 nm in radius.
48. Mohr D, Frey S, Fischer T, Guttler T, Gorlich D: **Characterisation of the passive permeability barrier of nuclear pore complexes**. *EMBO J* 2009, **28**:2541-2553.  
Based on studying the diffusion of 10 proteins through the NPCs in HeLa cells, the authors propose to model NPC passage via diffusion through a meshwork with three characteristic pore sizes and abundance frequencies.
49. Timney BL, Raveh B, Mironska R, Trivedi JM, Kim SJ, Russel D, Wente SR, Sali A, Rout MP: **Simple rules for passive diffusion through the nuclear pore complex**. *J Cell Biol* 2016, **215**:57-76.  
This work used time-resolved fluorescence microscopy to measure the passive diffusion time of GFP multimers of increasing sizes in yeast. The authors found no hard size cut-off for passage, but deduced an empirical power-law relationship between diffusion time constants and proteins sizes.
50. Bonner WM: **Protein migration into nuclei. I. Frog oocyte nuclei in vivo accumulate microinjected histones, allow entry to small proteins, and exclude large proteins**. *J Cell Biol* 1975, **64**:421-430.
51. Frey S, Rees R, Schunemann J, Ng SC, Funfgeld K, Huyton T, Gorlich D: **Surface properties determining passage rates of proteins through nuclear pores**. *Cell* 2018, **174**:202-217 e209.  
The authors investigate the relationship between the NPC passage rate of proteins and their surface properties. They found that exposed hydrophobic residues, as well as histidine, cysteine, and arginine facilitate, while negative charges and lysine inhibit NPC passage.
52. Chelsky D, Ralph R, Jonak G: **Sequence requirements for synthetic peptide-mediated translocation to the nucleus**. *Mol Cell Biol* 1989, **9**:2487-2492.
53. Robbins J, Dilworth SM, Laskey RA, Dingwall C: **Two interdependent basic domains in nucleoplasmic nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence**. *Cell* 1991, **64**:615-623.
54. Dong X, Biswas A, Chook YM: **Structural basis for assembly and disassembly of the CRM1 nuclear export complex**. *Nat Struct Mol Biol* 2009, **16**:558-560.
55. Kosugi S, Yanagawa H, Terauchi R, Tabata S: **NESmapper: accurate prediction of leucine-rich nuclear export signals**

- using activity-based profiles. *PLoS Comput Biol* 2014, **10**:e1003841.
56. Xu D, Marquis K, Pei J, Fu SC, Cagatay T, Grishin NV, Chook YM: **LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins.** *Bioinformatics* 2015, **31**:1357-1365.
  57. Kirli K, Karaca S, Dehne HJ, Samwer M, Pan KT, Lenz C, Urlaub H,
    - Gorlich D: **A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.** *eLife* 2015, **4**.
 Kirliet *al.* identified ~1k cargos for Exportin 1 using a differential pulldown in which the exportin is kept in either a binding or non-binding state. Differential binding was assayed with label-free proteomics.
  58. Aksu M, Pleiner T, Karaca S, Kappert C, Dehne HJ, Seibel K, Urlaub H, Bohnsack MT, Gorlich D: **Xpo7 is a broad-spectrum exportin and a nuclear import receptor.** *J Cell Biol* 2018, **217**:2329-2340.
  59. Mackmull MT, Klaus B, Heinze I, Chokkalingam M, Beyer A, Russell RB, Ori A, Beck M: **Landscape of nuclear transport receptor cargo specificity.** *Mol Syst Biol* 2017, **13**:962.
  60. Bohnsack MT, Stuken T, Kuhn C, Cordes VC, Gorlich D: **A selective block of nuclear actin export stabilizes the giant nuclei of Xenopus oocytes.** *Nat Cell Biol* 2006, **8**:257-263.
  61. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: **The protein data bank.** *Nucleic Acids Res* 2000, **28**:235-242.